PHRI researchers participated at the European Heart Rhythm Association (EHRA) 2026 Congress, with multiple presentations highlighting PHRI research.
Senior scientist Jeff Healey presented research from the LAAOS-4 trial, contributing to ongoing discussions around strategies to reduce stroke risk in patients with atrial fibrillation.
Scientist William McIntyre presented findings from the ARTESiA trial, focusing on cause of death and competing risk in patients with device detected atrial fibrillation treated with apixaban or aspirin.
Our international collaborators also shared new findings from ARTESiA:
- Maria Hee Jung Park Frausing (Germany) presented findings of a study on the relationship between subclinical atrial fibrillation and the risk of heart failure, simultaneously published in the European Journal of Heart Failure.
- Máté Vámos (Hungary) examined the association between body mass index and arrhythmia progression and outcomes in patients with subclinical atrial fibrillation.
- Julia Wiebke Erath (Denmark) presented findings on sex‑specific effects of apixaban versus aspirin in subclinical atrial fibrillation.
